Oncology Medical Home Measure Specification Data

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Oncology Medical Home Measure Specification Data"

Transcription

1 Oncology Medical Home Measure Specification Data Measure Name Chemotherapy pathway compliance Measure # 1 Measure Description % of chemotherapy treatments that have adhered to NCCN guidelines or pathways. Numerator Statement Use of any of the below and with a treatment that involved NCCN chemotherapy treatment guidelines of 2B or above. Denominator Statement Visits with one of the following criteria: Physician office: Initial chemotherapy injections, pushes, or infusions, (CPT codes 96413, 96401, 96402, 96409, 96413, 96416) and oral chemotherapy if initiated/ordered through an EMR. Hospital inpatient: DRG or Hospital outpatient: revenue codes: 331 chemotherapy injection or 335 chemotherapy infusion Measure Type Quality X Value Outcomes Community Oncology Alliance Contact A mechanism will be needed to identify the regimen as an NCCN approved 2B plan and a calculation of 2B regimens as a percentage of all regimens. This would apply to chemotherapy infusions, injections, pushes and oral chemotherapy ordered/initiated through an oncology EMR system. (Oral chemotherapy edits may be subject to technology advancements in EMR vendors.) Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) 2012 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org<http://www.nccn.org/>. NATIONAL COMPREHENSIVE CANCER NETWORK, NCCN, NCCN GUIDELINES, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

2 Measure Name Cancer staging documented. Measure # 2 Measure Description % of cancer patients with documented clinical or pathologic staging prior to initiation of first course of treatment. Numerator Statement Occurrences where AJCC cancer stage AND AJCC TNM values are present (T = tumor, N = nodes, M = metastases) are present when patient chemotherapy is initiated. Denominator Statement Patients with a ICD- 9 codes of Measure Type Quality X Value Outcomes American Medical Association - Physician Consortium for Performance Improvement Contact EMR vendors will need some type of audit in their systems for the initiation of the chemotherapy order. It would be preferable for the EMR system to STOP the chemotherapy ordering process if AJCC staging is not present. The user could receive a possible warning of Quality cancer treatment requires AJCC cancer staging be applied prior to the initiation of chemotherapy. Press CONTINUE if you wish to continue without staging. Press CANCEL if wish to obtain staging first. Press IGNORE to allow the physician to bypass the scoring system and input their estimated staging. The quality score will be impacted if the user enters CONTINUE or IGNORE. Staging required for diseases staged per AJCC guidelines and the audit should be against stage scoring system and not just the presence of a stage. (i.e., Presence of staging to be determined by TNM or other systematic scoring system. )

3 Measure Name Emergency room utilization Measure # 3 Measure Description # of emergency room visits per chemotherapy patient per year Numerator Statement Patients in the denominator list that also had an ER claim filed in the same period and within 30 days of a chemotherapy encounter. ER visits are identified as any UB92 claim that includes revenue codes for emergency room services OR emergency room professional fee revenue code of 981. AND Denominator Statement Primary diagnosis codes, or ranges of codes that are related to cancer, chemotherapy side effects, and symptom management related to either. Payers have their own list of these codes and the intent is to provide a complete and exhaustive list that is developed and endorsed by physicians from payers and cancer care communities and subsequently used by payers and providers. Depending on the reporting entity, the # of patients that have had at least one of the following in the reporting period. Hospital outpatient: revenue codes: 331 chemotherapy injection or 335 chemotherapy infusion or 332 for oral chemotherapy. Physician: Initial chemotherapy injections, pushes, or infusions, (CPT codes 96413, 96401, 96402, 96409, 96413, 96416) or any oral chemotherapy code QXXXX. Measure Type Quality Value X Outcomes This is a NCQA PCMH focus however; no detail is listed on how to gather this numerator. Likewise on NQF, there is mention of measuring with respect to other conditions but there is no mention on how to gather and who produces this information.. Contact Cancer centers are encouraged to gather this information for all of their patients regardless of payer. And, to use whatever mechanism to gather this information. Ideas to consider in order to gather this information include but are not limited to: 1) Automated or manual reporting from the hospital(s) to the cancer centers. 2) Utilization of an information exchange engine to gather and report this information. 3) Patient questionnaires at the time of the visit to the cancer center to determine if the patient has had a visit to an emergency room since their last visit. 4) Prompts, such a reminder attached to insurance cards, that would remind the patient, family or ER provider to contact the patient s oncology care team prior to providing emergency room services.

4 5) Any other means available to gather and report for the entire practice. A listing of proposed diagnosis codes for this measure and the hospital admissions measure will be proposed as a separate document. This document will require careful scrutiny by all participants on the OMH Steering Committee. The end goal will be a comprehensive list of filtered diagnosis codes that can be used by all providers, payers and the information systems that will be used to assist in these measures.

5 Measure Name Hospital admission rate Measure # 4 Measure Description # of hospital admissions per chemotherapy patient per year. Numerator Statement Patients in the denominator list that also had a hospital admission within 30 days of chemotherapy visit. Hospital admission visits are identified as any UB92 claim with a bill type (FL 4) of 111. AND Primary diagnosis codes, or ranges of codes that are related to cancer, chemotherapy side effects, and symptom management related to either. Payers have their own list of these codes and the intent is to provide a complete and exhaustive list that is developed and endorsed by physicians from payers and cancer care communities and subsequently used by payers and providers. Denominator Statement Depending on the reporting entity, the # of patients that have had at least one of the following in the reporting period. Hospital outpatient: revenue codes: 331 chemotherapy injection or 335 chemotherapy infusion or 332 for oral chemotherapy. Physician: Initial chemotherapy injections, pushes, or infusions, (CPT codes 96413, 96401, 96402, 96409, 96413, 96416) or any oral chemotherapy code QXXXX. Measure Type Quality Value X Outcomes This is a NCQA PCMH focus however no detail listed on how to gather numerator. Likewise on NQF, there is mention of measuring with respect to other conditions but there is no mention on how to gather this data and who produces the data. Contact Cancer centers are encouraged to gather this information for all of their patients regardless of payer. And, to use whatever mechanism to gather this information. Ideas to consider in order to gather this information include but are not limited to: 1) Automated or manual reporting from the hospital(s) to the cancer centers. 2) Utilization of an information exchange engine to gather and report this information. 3) Patient questionnaires at the time of the visit to the cancer center to determine if the patient has had a visit to an admission since their last visit. 4) Prompts, such a reminder attached to insurance cards, that would remind the patient, family or admitting office staff to contact the patient s oncology care team prior to admitting the patient. 5) Any other means available to gather and report this information for the entire practice. A listing of proposed diagnosis codes for this measure and the emergency room measure will be proposed as a separate document. This document will require

6 careful scrutiny by all participants on the OMH Steering Committee. The end goal will be a comprehensive list of filtered diagnosis codes that can be used by all providers, payers and the information systems that will be used to assist in these measures.

7 Measure Name Deaths of cancer patients while in a hospital. Measure # 5 Measure Description % of cancer patient deaths where the patient died in an acute care setting. Numerator Statement Of the cancer patients with recorded deaths in the reporting period (as defined in the numerator) the patients that died in an acute care setting. Denominator Statement Patients with a primary admission or principal discharge diagnosis code of cancer - ICD- 9 codes of or any other diagnosis code(s) directly related to cancer, treatment or side effects of either. (Specific diagnosis codes to be determined by all physicians on the OMH Steering Committee.) AND A death recorded in a specific time frame. The selection should be from the date and time the patient s date and location of death was recorded. Patients that expired in a skilled nursing facility. Measure Type Quality Value Outcomes X Listed as NQF measure 214 and with ASCO listed as steward but after steward listed as Institute for Clinical and Evaluative Sciences Contact EMR vendors are encouraged to do periodic sweeps of the National Death Registry to capture expiration data after a pre-determined number of missed appointments. Data capture process would also need to be sensitive of when death information was obtained and not just when patient expired. (Record the date of date and the date the death was recorded.) The listing of proposed diagnosis codes will be the same list used for emergency room visit and hospital admissions.

8 Measure Name Days in hospice care Measure # 6 Measure Description Average # of days under hospice care (home or inpatient) at time of death. Numerator Statement Numerator is not applicable with this calculation of average days. Each patient that meets the below criteria should be used to determine an average. Denominator Statement The Patients with a primary/principal diagnosis code of cancer - ICD- 9 codes of or any other diagnosis code(s) directly related to cancer, treatment or side effects of either. (Specific diagnosis codes to be determined by all physicians on the OMH Steering Committee.) AND Patients placed in an inpatient or at home hospice program. AND Recorded date of death in the reporting period. This measure selection should be from when the patient s recorded date of death. Patients in a skilled nursing facility. Measure Type Quality X Value X Outcomes National Cancer Institute through NQF measure 216 Contact EMR vendors are encouraged to develop and maintain data fields specific to hospice care, include place of death. EMR vendors are also encouraged to sweep the National Death Registry to gather date of death information for patients. Meaningful use requires outbound transitions. The above need should be considered in the implementation of Meaningful Use. Reporting procedures should allow for when the death data is received as well as when the patient expired. This procedure would assist with the timing delays for when this data is received. Practices should use whatever means available to capture and report hospice utilization data for their patients. Suggestions include: 1) Automated or manual reporting from the hospice to the cancer centers. 2) Utilization of an information exchange engine to gather and report this information. 3) Prompts, such a reminder attached to insurance cards, that would remind the patient, family or hospice staff to contact the patient s oncology care team prior to admitting the patient to hospice. 4) Any other means available to gather and report this information for the entire practice. The listing of diagnosis codes will be the same list used for emergency room visits, hospital admissions and expirations in an acute care setting.

9 Measure Name End of life discussions Measure # 7 Measure Description % of patients that have newly diagnosed Stage IV disease who have had advance care planning discussions documented. Numerator Statement The number of patients from the denominator that have a documented, comprehensive and appropriate discussion regarding choices and decisions regarding their care. Although topics are suggested below, the discussion will be at the direction and discretion of the provider. The communication must be documented, separate or within the physician note. Suggested topics include: Designated person to make decisions for the patient. The types of medical care preferred. The comfort level that is preferred. Preferred place of care. How the patient prefers to be treated by others. What the patient wishes others to know. Timeframes New diagnosis of stage IV disease: Within 60 days of initial treatment Denominator Statement Patients being measured in this category are cancer patients (with ICD-9 diagnosis code of ) AND stage IV disease. Stage IV to be determined as progressive staging or initial diagnosis and within the reporting period indicated. Measure Type Quality Value X Outcomes University of NC Chapel Hill through NQF measure 1641 Contact The payers on the OMH Steering Committee are very sensitive to this measure and request this measure goes beyond a simple Y/N answer that the provider discussed end of life issues with the patient. The definition and components of end of life discussions needs to be defined in this measure. The above is taken from the 5 Wishes program. 5 Wishes is a patient friendly living will program that is legally accepted in 40 states. This measure will require the top three components for this measure regardless of whether 5 Wishes is used for this measure. More information on 5 Wishes can be found at:

10 Measure Name Breast cancer survival rates Measure # 8 Measure Description Survival rates of stage I through IV breast cancer patients Numerator Statement There will not be a numerator in this measure. This measure will be the total percentage of breast cancer patients that have lived beyond 5 years. Denominator Statement The selection criteria for patients in this measure will include patients with any diagnosis code of through AND were reported as deceased during the reporting period OR were alive during the reporting period. If the patient was deceased during the reporting period the survival rate would be calculated from date of death to the diagnosis date. If the patient is alive the survival rate would be calculated from the current date to the diagnosis date. The five year survival rate by stage would be calculated from a sort and grouping of all of these patients by initial stage that have lived five years or beyond as a percentage of all breast cancer patients listed. Measure Type Quality Value Outcomes X Community Oncology Alliance Contact 5 years survival rates seem to be the accepted standard measurement and easier to embrace than an average life expectancy calculation. The ratio should be the % of patients from their initial stage and that have lived beyond 5 years from their initial diagnosis date and initial stage. Staging will be determined accurate if automated by the appropriate staging software. EMR vendors are encouraged to sweep the National Death Registry for date of death information for patients as appropriate.

11 Measure Name Colorectal cancer survival rates Measure # 9 Measure Description Survival rates of stage I through IV colorectal cancer patients Numerator Statement There will not be a numerator in this measure. This measure will be the total percentage of colorectal cancer patients that have lived beyond 5 years. Denominator Statement The selection criteria for patients in this measure will include patients with any diagnosis code of through AND were reported as deceased during the reporting period OR were alive during the reporting period. If the patient was deceased during the reporting period the survival rate would be calculated from date of death to the diagnosis date. If the patient is alive the survival rate would be calculated from the current date to the diagnosis date. The five year survival rate by stage would be calculated from a sort and grouping of all of these patients by initial stage that have lived five years or beyond as a percentage of all colorectal cancer patients listed. Measure Type Quality Value Outcomes X Community Oncology Alliance Contact 5 years survival rates seem to be the accepted standard measurement and easier to embrace than an average life expectancy calculation. The ratio should be the % of patients from their initial stage that have lived beyond 5 years from their initial diagnosis date and initial stage. Staging will be determined accurate if automated by the appropriate staging software. EMR vendors are encouraged to sweep the National Death Registry for date of death information for patients as appropriate.

12 Measure Name Lung cancer survivor rates Measure # 10 Measure Description Survival rates of stage I through IV NSC lung cancer patients Numerator Statement There will not be a numerator in this measure. This measure will be the total percentage of lung cancer patients that have lived beyond 5 years. Denominator Statement The selection criteria for patients in this measure will include patients with any diagnosis code of through AND were reported as deceased during the reporting period OR were alive during the reporting period. If the patient was deceased during the reporting period the survival rate would be calculated from date of death to the diagnosis date. If the patient is alive the survival rate would be calculated from the current date to the diagnosis date. The five year survival rate by stage would be calculated from a sort and grouping of all of these patients by initial stage that have lived five years or beyond as a percentage of all lung cancer patients listed. Measure Type Quality Value Outcomes X Contact 5 years survival rates seem to be the accepted standard measurement and easier to embrace than an average life expectancy calculation. The ratio should be the % of patients from their initial stage, that have lived beyond 5 years from their initial diagnosis date and initial stage. Staging will be determined accurate if automated by the appropriate staging software. EMR vendors are encouraged to sweep the National Death Registry for date of death information for patients as appropriate.

13 Measure Name Neutropenia risk Measure # 11 Measure Description % of cancer patients undergoing treatment with a chemotherapy regimen with a 20% or more risk of developing neutropenia and also received GCSF/white cell growth factor. Numerator Statement The number of occurrences where a patient received a colony stimulating factor for neutropenia risk of 20% or more with the drugs associated with infusions described in the denominator below. Denominator Statement Physician office: Initial chemotherapy injections, pushes, or infusions, (CPT codes 96413, 96401, 96402, 96409, 96413, 96416) with chemotherapy agents (HCPCS J9XXX) Hospital inpatient: DRG or Hospital outpatient or inpatient: revenue codes: 331 chemotherapy injection or 332 oral chemotherapy or 335 chemotherapy infusion Measure Type Quality X Value Outcomes ASCO via QOPI for specific regimens Contact Robert Hauser In order to be completely accurate this measure should also incorporate inappropriate (or overuse) use of GCSF. See below for a suggested formula that incorporates appropriate and inappropriate use. Neutropenia risk is determined by NCCN will be considered the standard for risks of 20% or more. Although the patient s medical status and condition may have implied risks for neutropenia, this phase of measurement will consider the risk associated with the regimen only. EMR, inventory management, or pathway management tools are expected to assist with the capture and reporting of this information. 20% risk also matches ASCO guidelines. Although a patient s specific comorbities and complications may increase their risk for neutropenia, this definition will be specific to NCCN guidelines only. This will necessitate a benchmark target of 85%.. Suggested formula: (Chemotherapy administrations with a 20% or more risk of febrile neutropenia that also included appropriate use of GCSF/ (chemotherapy administrations that call for GCSF use + GCSF administrations that were not warranted based on documented

14 febrile neutropenia risk factors.) Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) 2012 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org<http://www.nccn.org/>. NATIONAL COMPREHENSIVE CANCER NETWORK, NCCN, NCCN GUIDELINES, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

15 Measure Name Psycho/social screening and intervention Measure # 12 Measure Description % of chemotherapy patients that received psycho/social screening and received measurable interventions as a result of the psycho/social screening. This screening to be completed through an endorsed and recognizable program or procedure. Numerator Statement Denominator Statement This numerator has two parts; screenings applied to patients eligible for screening (new cancer patients) and patients that received interventions when interventions were appropriate. The denominator for this measure will also have two parts; patients needing screening (new cancer patients) and patients that were screened. (See below for calculations) Follow-up screening is not addressed in this screening. Measure Type Quality X Value Outcomes Community Oncology Alliance Contact This area is one of the most sensitive and possibly overlooked and undertreated areas in cancer care. Although it is a QOPI measure, practices often struggle with the screening and the subsequent needed interventions. Screenings should occur within 45 days of a first patient visit and not necessarily to be the first visit. The measure recommends screening and interventions specific to the following areas: Emotions related to cancer Changing behaviors Material and logistical resources Disruptions in work, school or family Financial advice and assistance It is also assumed that these areas, also important to psycho/social screening, are addressed in other patient communication and coordination procedures necessary for quality cancer care: Cancer treatment information Managing the illness When at all possible this process of screening and requesting of interventions should be automated and streamlined via technology based psycho/social screening/intervention tools.

16 An intervention is indicated when a patient requests an intervention. (Example: A cancer patient may indicate depression but may not desire or request intervention at that moment in their journey.) Acceptable interventions would be articles, communications and/or referrals to other professionals. Implementation is very important with this measure. This measure has potential to add financial and administrative burden if efficient tools and technologies are not used in the process. Sample calculation for this measure. The measure is based on eligible patients and not eligible interventions. # of eligible patients (# of new cancer patients) # of new patients that received screening of any type # of new patients that received any interventions. Patients not needing interventions would be counted as an intervention delivered. And using hypothetical numbers of 100 new patients: Example 1: 95 patients got screened and 95 patients received some type of intervention or no intervention was needed = (95/100)*(95/95) = 95% Example 2: 95 patients got screened and 80 patients received some type of intervention or no intervention was needed = (95/100)*(80/95) = 80%

17 Measure Name Patient receives treatment plan Measure # 13 Measure Description % of cancer patients that received a treatment plan prior to the administration of chemotherapy. This treatment plan to either be from a recognized source or to have required elements/components. Numerator Statement Number of components met of the total potential components for the reporting period. Denominator Statement The denominator for this measure will include the quantity of patients that begin chemotherapy and received a treatment plan with the following minimum components. Diagnosis including histology and stage Goal or intent of therapy (Curative, adjuvant etc.) Chemotherapy regimen and starting doses Duration and/or planned number of cycles and frequency. Information on possible side effects of treatment and symptoms of such effects. Listing of cancer-related resources and information. Contact information to all aspects of the care/support team and instructions on who to call for what so that the patient and family receives the best possible outcome with the highest quality and value. Measure Type Quality Value Outcomes AMA through NQF Measure 0381 (Radiation) Contact Treatment plans and planning is a concept that is used loosely and has broad meaning. A lot of cancer support organizations have their own definition and description of what they are and how they are used. This measure is intended to create a detailed definition and what is included in a treatment summary while also allowing it to be measured. The above is the minimal set of recommended criteria. Cancer centers are encouraged to expand upon this list as appropriate Treatment plans should be friendly, easy to understand and shared with the patient. Guidelines on the content of treatment plans are likely to get more stringent as time passes. Treatment plans should be prepared and presented to patients without requiring additional physician intervention. Proposed calculation:

18 # of eligible patients (# of new cancer patients) # of treatment summary components And using hypothetical numbers of 100 new patients: Example 1: 95 of 100 patients received 6 of 7 treatment plan components = (6*95)/(7*100) 81.4% Example 2: 45 of 100 patients received 7 of 7 treatment plan components and 40 of 100 patients received 6 of 7 components = ((45*7)+(40*6))/(7*100) = 79.3%

19 Measure Name Patient receives survivorship plan. Measure # 14 Measure Description % of cancer patients that received a survivorship plan within 45 days after the completion of chemotherapy. This survivorship plan to either be from a recognized source or to have required elements/components. Numerator Statement Number of components met of the total potential components for the reporting period. Denominator Statement The denominator for this measure will include the quantity of patients that have completed therapy within the last 45 days multiplied by the number of minimum components of a survivorship plan. The minimum components are noted below and are excerpts from the Institute of Medicine and the Commission on Cancer from the American College of Surgeons. Frequency and/or scheduled appointments with the oncologists and diagnostic testing. Listing and schedules of periodic and recommended cancer and other screenings, tests and exams and who would perform them. Information on possible long term side effects of treatment, symptoms of such effects, and how to report them. In addition to other reportable signs and symptoms. Recommendations for healthy behaviors. (Wellness, diet and exercise) Listing of cancer-related resources and information regarding cancer survivorship. Patients that are enrolled in hospice would be excluded from this calculation. Measure Type Quality Value Outcomes Institute of Medicine and American College of Cancer Commission on Cancer Contact There seems to be lots of discussion and confusion on the specifics of this item. Some include any discussion, visit or interaction post treatment as a component of a survivorship plan. Since the OMH model includes other measures for end of life issues and psycho/social screening, this measure will focus on the communication, coordination and interaction that should occur with the patient after scheduled chemotherapy is completed. Psycho/social screening and end of life discussions will be referenced in the survivorship plan but will be addressed as their own measures. Minimal requirements for a survivorship plan were defined by the Institute of Health in The American College of Surgeons also acknowledges these standards as the authority for survivorship plans. Refer to the following for more information: Fact-Sheet.pdf

20 NCCN References on survivorship: The above list is a subset of that recommended by these entities. Proposed calculation: # of eligible patients (# of new cancer patients) # of survivorship plan components And using hypothetical numbers of 100 new patients: Example 1: 90 of 100 patients received 4 of 5 treatment plan components = (90*4)/(100*5) = 72% Example 2: 43 of 100 patients received 5 of 5 treatment plan components and 40 of 100 patients received 4 of 5 components = ((45*5)+(40*4))/(5*100) = 73%

21 Measure Name Chemotherapy received near end of life. Measure # 15 Measure Description A measurement of chemotherapy given near end of life. Numerator Statement Physician office: Patients with one of the following Initial chemotherapy billing codes for injections, pushes, or infusions, (CPT codes 96413, 96401, 96402, 96409, 96413, 96416) within 30 days from date of death.. Hospital outpatient or inpatient: Patients with a revenue codes of 331 chemotherapy injection or 335 chemotherapy infusion within 30 days from date of death.. Denominator Statement Patients with a date of death recorded in this reporting period. Oral chemotherapy will be excluded from this calculation. Measure Type Quality X Value X Outcomes NQF measure 210 National Cancer Institute Contact The NQF measure indicates patients that received chemotherapy within the last 14 days of life. However, we feel that this calculation is not aggressive enough in the promotion/support of end of life care and hospice services. Suggested reporting procedure: Select patients with date of death recorded in the reporting period. Report last chemotherapy date for these patients. Record the % of patients with chemotherapy service dates less than or equal to 30 days before the actual date of death.

22 Measure Name Appropriate antiemetic for the appropriate treatment. Measure # 16 Measure Description Antiemetic drugs given appropriately with chemotherapy treatments. Numerator Statement The treatments described that received one of the approved antiemetic drugs for the specific chemotherapy drugs given and at the prescribed dose. Denominator Statement Physician office: Initial chemotherapy injections, pushes, or infusions, (CPT codes 96413, 96401, 96402, 96409, 96413, 96416) with chemotherapy agents (HCPCS J9XXX) Hospital inpatient: DRG or Hospital outpatient or inpatient: revenue codes: 331 chemotherapy injection or 332 oral chemotherapy or 335 chemotherapy infusion Oral chemotherapy will be excluded at this time. Measure Type Quality X Value Outcomes Community Oncology Alliance Contact Bo Gamble Proper antiemetic is dependent upon the dose of the oncology drug administered. A different antiemetic may be required for the same oncology drug with a higher or lower dose. Specific antiemetics are recommended based on the emetogenic level of a dose of a specific chemotherapy drug. This matrix of possibilities is complicated and is based on a high, moderate, low and minimal levels of risk. Given the complications of this issue and the need for standardization in this measure, NCCN indications will be the standard for each regimen. It is highly recommended/suggested that EMR vendors, inventory management tools and pathway management tools facilitate the capture and reporting of proper antiemetic use. NCCN guidelines for antiemetic use can be found at: Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) 2012 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org<http://www.nccn.org/>. NATIONAL COMPREHENSIVE CANCER NETWORK, NCCN, NCCN GUIDELINES, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

23 Measure Name Measure Description Numerator Statement Appropriate use of advanced imaging for early stage breast cancer patients. Measure # 17 % of patients with early-stage breast cancer patients that did not receive advanced imaging technologies to determine cancer s spread. Number of patients that fit the denominator description and did NOT HAVE any PET, CT, or MRI CPT codes in the range of Denominator Statement Number of stage 0, I or II breast cancer patients (ICD9-CM codes or or Measure Type Quality Value X Outcomes American Society of Clinical Oncology Contact Newly identified stage I or II breast cancer or ductal carcinoma in situ (DCIS), which are unlikely to have spread beyond the breast and nearby lymph nodes at the time of diagnosis. (In these patients, staging is done according to a physical examination, the size of the tumor and nearby lymph nodes, and common blood tests.) For these patients, the use of advanced imaging technologies to search for cancer spread has not been shown to improve detection of additional tumors or to extend survival. Rather, these tests are known to increase the risk of misdiagnosis or falsepositive results, which can lead to unnecessary invasive procedures or treatments that can ultimately diminish quality of life or even shorten patients' lives.

24 Measure Name Measure Description Numerator Statement Appropriate use of advanced imaging for early stage prostate cancer patients. Measure # 18 % of patients with early-stage prostate cancer patients that did not receive advanced imaging technologies to determine cancer s spread. Number of patients that fit the denominator description and did NOT HAVE any PET, CT, or MRI CPT codes in the range of Denominator Statement Number of stage 0, I or II prostate cancer patients (ICD9-CM code 185) Measure Type Quality Value X Outcomes American Society of Clinical Oncology Contact Newly diagnosed low-grade prostate cancer (Gleason score less than or equal to 6) in men with a PSA level of less than 10 ng/ml. For these patients, the use of advanced imaging technologies to search for cancer spread has not been shown to improve detection of additional tumors or to extend survival. Rather, these tests are known to increase the risk of misdiagnosis or falsepositive results, which can lead to unnecessary invasive procedures or treatments that can ultimately diminish quality of life or even shorten patients' lives.

25 Measure Name Presence of patient performance status prior to treatment Measure # 19 Measure Description % of patients with a documented performance status prior to beginning chemotherapy. Numerator Statement Presence of ECOG or Karnofsky or WHO performance status when patient chemotherapy is initiated. Denominator Statement Patients with a ICD- 9 codes of Measure Type Quality X Value X Outcomes Community Oncology Alliance Contact Bo Gamble EMR vendors will need some type of audit in their systems to assure performance status is documented prior to the initiation of the chemotherapy order. It would be preferable for the EMR system to STOP the chemotherapy ordering process if performance status is not present. The user could receive a possible warning of Quality cancer treatment requires patient performance status prior to the initiation of chemotherapy. Press CONTINUE if you wish to continue without this status indicator. Press CANCEL if wish to obtain this indicator first. Press IGNORE to allow the physician to bypass this requirement and input their chemotherapy order. The quality score will be impacted if the user enters CONTINUE or IGNORE.

Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care

Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care John Fox, MD MHA Senior Medical Director Priority Health 1 Cancer Care is the Leading Edge of Medical Cost Trend for

More information

When the diagnosis is cancer, many people

When the diagnosis is cancer, many people Hard decisions about cancer 5 tests and treatments to question When the diagnosis is cancer, many people understandably want to pull out all the stops to treat it. But some tests, treatments, and procedures

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

Secondary Uses of Data for Comparative Effectiveness Research

Secondary Uses of Data for Comparative Effectiveness Research Secondary Uses of Data for Comparative Effectiveness Research Paul Wallace MD Director, Center for Comparative Effectiveness Research The Lewin Group Paul.Wallace@lewin.com Disclosure/Perspectives Training:

More information

UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions

UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions Q1. What members are impacted by the UnitedHealthcare Injectable Chemotherapy PA Program? A. Beginning

More information

Chapter 13. The hospital-based cancer registry

Chapter 13. The hospital-based cancer registry Chapter 13. The hospital-based cancer registry J.L. Young California Tumor Registry, 1812 14th Street, Suite 200, Sacramento, CA 95814, USA Introduction The purposes of a hospital-based cancer registry

More information

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.

More information

Follow-up care plan after treatment for breast cancer. A guide for General Practitioners

Follow-up care plan after treatment for breast cancer. A guide for General Practitioners Follow-up care plan after treatment for breast cancer A guide for General Practitioners This leaflet provides information for GPs on the follow-up care required by women who had breast cancer. It is for

More information

Survivorship Care Plans Guides for Living After Cancer Treatment

Survivorship Care Plans Guides for Living After Cancer Treatment Survivorship Care Plans Guides for Living After Cancer Treatment Institute of Medicine Report 2005 Recommendations for meeting needs of cancer survivors Implement survivorship care plan Build bridges

More information

Tricia Cox on 7/18/2012 at Oncology Center. Sarah Randolf. Female

Tricia Cox on 7/18/2012 at Oncology Center. Sarah Randolf. Female SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,

More information

CPT only copyright 2014 American Medical Association. All rights reserved. 10/10/2014 Page 537 of 593

CPT only copyright 2014 American Medical Association. All rights reserved. 10/10/2014 Page 537 of 593 Measure #391 (NQF 0576): Follow-Up After Hospitalization for Mental Illness (FUH) National Quality Strategy Domain: Communication and Care Coordination 2015 PHYSICIAN QUALITY REPTING OPTIONS F INDIVIDUAL

More information

Guide to Understanding Breast Cancer

Guide to Understanding Breast Cancer An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients

More information

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James

More information

ONCOLOGY MEDICAL HOME UPDATE. Bruce Gould, MD Medical Director OMH Steering Committee Chair

ONCOLOGY MEDICAL HOME UPDATE. Bruce Gould, MD Medical Director OMH Steering Committee Chair ONCOLOGY MEDICAL HOME UPDATE Bruce Gould, MD Medical Director OMH Steering Committee Chair Oncology Medical Home Summary Model Identify Stakeholder Needs Define Model Elements Develop Accreditation Program

More information

Cancer Care Delivered Locally by Physicians You Know and Trust

Cancer Care Delivered Locally by Physicians You Know and Trust West Florida Physician Office Building Johnson Ave. University Pkwy. Olive Road N. Davis Hwy. For more information on West Florida Cancer Center: 850-494-5404 2130 East Johnson Avenue Pensacola, Florida

More information

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence.

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Leaders in Prostate Cancer Treatment and Research The Center for Prostate Cancer at the North

More information

Cancer research in the Midland Region the prostate and bowel cancer projects

Cancer research in the Midland Region the prostate and bowel cancer projects Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate

More information

Report with statistical data from 2007

Report with statistical data from 2007 2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,

More information

Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer

Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer Michael Stokes United BioSource Corporation ISPOR 13 th Annual International Meeting Toronto,

More information

2010 National Survey. Newham University Hospital NHS Trust

2010 National Survey. Newham University Hospital NHS Trust National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department

More information

EMR Designed For Physicians By Physicians

EMR Designed For Physicians By Physicians EMR Designed For Physicians By Physicians Focused on the Practice PegasusEMR has a unique heritage in the medical software industry. It was designed by a team of Physicians who, along with a team of process

More information

Big Data and Oncology Care Quality Improvement in the United States

Big Data and Oncology Care Quality Improvement in the United States Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation

More information

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer Prostate Cancer Guide A resource to help answer your questions about prostate cancer Thank you for downloading this guide to prostate cancer treatment. We know that all the information provided online

More information

Measure #130 (NQF 0419): Documentation of Current Medications in the Medical Record National Quality Strategy Domain: Patient Safety

Measure #130 (NQF 0419): Documentation of Current Medications in the Medical Record National Quality Strategy Domain: Patient Safety Measure #130 (NQF 0419): Documentation of Current Medications in the Medical Record National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:

More information

2012 Oncology Service Line Goals and Accomplishments

2012 Oncology Service Line Goals and Accomplishments 2012 Oncology Service Line Goals and Accomplishments 2012 Program goals and outcomes Quality and Service Seek NAPBC accreditation by December 31, 2012 Application was accepted; visit date set for April

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including

More information

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women

More information

Section 6. Medical Management Program

Section 6. Medical Management Program Section 6. Medical Management Program Introduction Molina Healthcare maintains a medical management program to ensure patient safety as well as detect and prevent fraud, waste and abuse in its programs.

More information

PSA Screening for Prostate Cancer Information for Care Providers

PSA Screening for Prostate Cancer Information for Care Providers All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits

More information

What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide

What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide A M E R I C A N C O L L E G E O F C H E S T P H Y S I C I A N S Lung cancer is one of the most common cancers. About 170,000

More information

Attribute appropriate and inappropriate services to provider of initial visit

Attribute appropriate and inappropriate services to provider of initial visit Optimal Care for Acute Low Back Pain - Adults Primary Care Description The rate represents the percentage of members ages 18 and older with newly diagnosed acute low back pain who received optimal care

More information

TREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE

TREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE Providing the best in cancer care for Veterans TREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE VA Pittsburgh s state-of-the-art TomoTherapy machine, which delivers radiation to patients.

More information

XIV ANNUAL MEETING OF NURSING

XIV ANNUAL MEETING OF NURSING Archive of Oncology 2000;8(Suppl 1):69. SESSION 5 XIV ANNUAL MEETING OF NURSING 69 Archive of Oncology 2000;8(Suppl 1):70. 70 UDC: 616.34-007.272:616-089.8:614.39 I. GAJI M. ULAFI Æ. MIHAJLOVI R. NE I

More information

What You Need to Know for the Upcoming Transition to ICD-10. Written by the AMA CPT Medical Informatics Department

What You Need to Know for the Upcoming Transition to ICD-10. Written by the AMA CPT Medical Informatics Department What You Need to Know for the Upcoming Transition to ICD-10 Written by the AMA CPT Medical Informatics Department W H I T E P A P E R J U N E 2 0 1 2 This white paper is for educational purposes only and

More information

HOW TO FILE ACCIDENT AFLAC CLAIM

HOW TO FILE ACCIDENT AFLAC CLAIM HOW TO FILE ACCIDENT AFLAC CLAIM Step 1: Please complete the attached Accident Claim Form and follow the check list guidelines below. Have the patient or policy holder complete and sign Page 1 & 2 Sign

More information

Treatment & Research. Treatment & Research

Treatment & Research. Treatment & Research Treatment & Research In March 1990, I became ill while on a trip to Thailand. I was examined and tested and given instructions to go to the emergency room when I arrived at home. In Great Falls, I learned

More information

Procedures for Coding Inpatient Medical Record Cases for the CCS Examination

Procedures for Coding Inpatient Medical Record Cases for the CCS Examination Procedures for Coding Inpatient Medical Record Cases for the CCS Examination Instructions and official guidelines for coding medical records are included in the following resources: ICD-10-CM/PCS, CPT,

More information

Lung Cancer Consultant Outcomes Publication

Lung Cancer Consultant Outcomes Publication Lung Cancer Consultant Outcomes Publication Introduction This report describes the outcomes of individual consultant thoracic and cardiothoracic surgeons who carry out surgery for lung cancer. It has been

More information

Metastatic Breast Cancer...

Metastatic Breast Cancer... DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a

More information

2014 Report of Cancer Program Activities for 2013

2014 Report of Cancer Program Activities for 2013 2014 Report of Cancer Program Activities for 2013 The University of Vermont Health Network-Central Vermont Medical Center (UVMHN-CVMC) Cancer Committee is pleased to present our Cancer Program Annual Report

More information

2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)

2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older) 2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older) IMPTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered satisfactory

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

Behavioral Health Phase 3: Standards Under Review

Behavioral Health Phase 3: Standards Under Review Behavioral Health Phase 3: Standards Under Review Measure Number Title Description Measure Steward 0108 Follow-Up Care for Children Prescribed ADHD Medication (ADD) The percentage of children newly prescribed

More information

METASTASES TO THE BONE

METASTASES TO THE BONE RADIATION THERAPY FOR METASTASES TO THE BONE Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY WHAT ARE BONE METASTASES? Cancer that starts

More information

Adjuvant Therapy for Breast Cancer: Questions and Answers

Adjuvant Therapy for Breast Cancer: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast

More information

ONCOLOGY MANAGEMENT. Controlling Cancer-Related. Costs in Your Population. Intelligent Value. October 2012

ONCOLOGY MANAGEMENT. Controlling Cancer-Related. Costs in Your Population. Intelligent Value. October 2012 ONCOLOGY MANAGEMENT Controlling Cancer-Related Costs in Your Population October 2012 ACCREDITED CASE MANAGEMENT DISEASE MANAGEMENT HEALTH UTILIZATION MANAGEMENT Intelligent Value Our URAC accredited care

More information

Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care

Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care Patricia A. Ganz, M.D. Jonsson Comprehensive Cancer Center UCLA Schools of Medicine & Public Health Overview of Presentation

More information

Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required]

Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: Revised: This policy applies

More information

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the

More information

Health Information. Technology and Cancer Information Management. Health Information Technology & Cancer Information Management 363

Health Information. Technology and Cancer Information Management. Health Information Technology & Cancer Information Management 363 Health Information Technology & 363 Health Information Technology and Cancer Information Management Opportunities in the health information field have expanded with changes in health care delivery, utilization

More information

When it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month

When it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month For Immediate Release Oct. 8, 2012 When it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month SEATTLE Oncologists and researchers are discovering that when it

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

PTE Pediatric Asthma Metrics Reporting Updated January 2015

PTE Pediatric Asthma Metrics Reporting Updated January 2015 PTE Pediatric Asthma Metrics Reporting Updated January 20 Introduction: The Maine Health Management Coalition s (MHMC) Pathways to Excellence (PTE) Program is preparing for its next round of PTE Pediatric

More information

Using Medicare Hospitalization Information and the MedPAR. Beth Virnig, Ph.D. Associate Dean for Research and Professor University of Minnesota

Using Medicare Hospitalization Information and the MedPAR. Beth Virnig, Ph.D. Associate Dean for Research and Professor University of Minnesota Using Medicare Hospitalization Information and the MedPAR Beth Virnig, Ph.D. Associate Dean for Research and Professor University of Minnesota MedPAR Medicare Provider Analysis and Review Includes information

More information

GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision

GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision RADIATION THERAPY FOR GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT GYNECOLOGIC CANCERS Gynecologic cancers

More information

EDUCATING, SUPPORTING & COORDINATING CARE: ONCOLOGY NURSE NAVIGATORS

EDUCATING, SUPPORTING & COORDINATING CARE: ONCOLOGY NURSE NAVIGATORS EDUCATING, SUPPORTING & COORDINATING CARE: ONCOLOGY NURSE NAVIGATORS Nancy Foreman, RN, BSN Oncology Nurse Navigator Cancer Centers of Northern Arizona Healthcare Learning Objectives: Identify five services

More information

Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.

Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too. Male Breast Cancer Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too. Many people do not know that men can get breast

More information

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Presented by Susan Haviland, BSN RN Senior Consult, Santa Rosa Consulting Meaningful Use Quality Measures Centers for Medicare and Medicaid Services

More information

Cancer Treatment Benefit

Cancer Treatment Benefit Cancer Treatment Benefit In Hong Kong, more than 27,000 men and women are newly-diagnosed with cancer each year 1, which means on average one new case is recorded every 20 minutes. Currently 1 in 4 men

More information

The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options

The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options Why We re Here The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options What Are Lungs? What Do They Do? 1 Located in the chest Allow you to breathe Provide oxygen

More information

Iowa Wellness Plan Benefits Coverage List

Iowa Wellness Plan Benefits Coverage List Iowa Wellness Plan Benefits Coverage List Service Category Covered Duration, Scope, exclusions, and Limitations Excluded Coding 1. Ambulatory Services Primary Care Illness/injury Physician Services Should

More information

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.

More information

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What? RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which

More information

Overview. Provider Qualifications

Overview. Provider Qualifications Overview Diabetes self management training (DSMT) is a collaborative process through which patients with diabetes gain knowledge and skills needed to modify behavior and successfully manage the disease

More information

2009 Cancer Committee

2009 Cancer Committee 2009 Cancer Committee Lung (non-small cell) Cancer Study Stage IIIA and IIIB John Clouse, M.D. Alicia Stark, RHIT Jeff Robinson Table of Cont ent s Table of Contents... 1 Lung (non-small cell) Cancer Facts.2

More information

Office ID Location: City State Date / / PRIMARY CARE SURVEY

Office ID Location: City State Date / / PRIMARY CARE SURVEY A. Organizational Characteristics PRIMARY CARE SURVEY We want to learn more about the general features of your office. A1. What health-related services does your office provide (check all that apply)?

More information

To precertify inpatient admissions or transitional care services, call 1-866-688-3400 and select option #1.

To precertify inpatient admissions or transitional care services, call 1-866-688-3400 and select option #1. Security Health Plan provides coverage of various mental health/aoda (alcohol and other drug abuse) benefits to individual and employer group members. These benefits are managed by Security Health Plan.

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #143 (NQF 0384): Oncology: Medical and Radiation Pain Intensity Quantified National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

Regulatory Compliance Policy No. COMP-RCC 4.07 Title:

Regulatory Compliance Policy No. COMP-RCC 4.07 Title: I. SCOPE: Regulatory Compliance Policy No. COMP-RCC 4.07 Page: 1 of 7 This policy applies to (1) any Hospital in which Tenet Healthcare Corporation or an affiliate owns a direct or indirect equity interest

More information

An Introduction to the American Cancer Society & Primary Care Systems Work. Presented by: Jessica Jamison, MPH Sr. Director, Primary Care Systems

An Introduction to the American Cancer Society & Primary Care Systems Work. Presented by: Jessica Jamison, MPH Sr. Director, Primary Care Systems An Introduction to the American Cancer Society & Primary Care Systems Work Presented by: Jessica Jamison, MPH Sr. Director, Primary Care Systems Who We Are Mission Statement: The American Cancer Society

More information

CODING. Neighborhood Health Plan 1 Provider Payment Guidelines

CODING. Neighborhood Health Plan 1 Provider Payment Guidelines CODING Policy The terms of this policy set forth the guidelines for reporting the provision of care rendered by NHP participating providers, including but not limited to use of standard diagnosis and procedure

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

See page 331 of HEDIS 2013 Tech Specs Vol 2. HEDIS specs apply to plans. RARE applies to hospitals. Plan All-Cause Readmissions (PCR) *++

See page 331 of HEDIS 2013 Tech Specs Vol 2. HEDIS specs apply to plans. RARE applies to hospitals. Plan All-Cause Readmissions (PCR) *++ Hospitalizations Inpatient Utilization General Hospital/Acute Care (IPU) * This measure summarizes utilization of acute inpatient care and services in the following categories: Total inpatient. Medicine.

More information

The Official Guidelines for coding and reporting using ICD-9-CM

The Official Guidelines for coding and reporting using ICD-9-CM Reporting Accurate Codes In the Era of Recovery Audit Contractor Reviews Sue Roehl, RHIT, CCS The Official Guidelines for coding and reporting using ICD-9-CM A set of rules that have been developed to

More information

Monitoring Clinical Stage to Improve Care

Monitoring Clinical Stage to Improve Care Monitoring Clinical Stage to Improve Care Stephen Dreyer, MD, FACS Cancer Liaison State Chair Nebraska Fremont, NE M. Asa Carter, CTR Manager, Accreditation and Standards American College of Surgeons Chicago,

More information

Meaningful Use. Medicare and Medicaid EHR Incentive Programs

Meaningful Use. Medicare and Medicaid EHR Incentive Programs Meaningful Use Medicare and Medicaid Table of Contents What is Meaningful Use?... 1 Table 1: Patient Benefits... 2 What is an EP?... 4 How are Registration and Attestation Being Handled?... 5 What are

More information

Explanation of care coordination payments as described in Section 223.000 of the PCMH provider manual

Explanation of care coordination payments as described in Section 223.000 of the PCMH provider manual Explanation of care coordination payments as described in Section 223.000 of the PCMH provider manual Determination of beneficiary risk Per beneficiary amounts Per beneficiary amounts 1 For the first year

More information

PREVENTIVE MEDICINE AND SCREENING POLICY

PREVENTIVE MEDICINE AND SCREENING POLICY REIMBURSEMENT POLICY PREVENTIVE MEDICINE AND SCREENING POLICY Policy Number: ADMINISTRATIVE 238.13 T0 Effective Date: January 1, 2016 Table of Contents APPLICABLE LINES OF BUSINESS/PRODUCTS... APPLICATION...

More information

News from the NCCN 18 th Annual Conference Advancing the Standard of Cancer Care

News from the NCCN 18 th Annual Conference Advancing the Standard of Cancer Care News from the NCCN 18 th Annual Conference Advancing the Standard of Cancer Care 2013 FCDS Annual Meeting July 26, 2013 Judy Bonner, RN, MS, CTR Mayra Espino, BA, RHIT, CTR NCCN Highlights Roundtable The

More information

Healthy Living with Diabetes. Diabetes Disease Management Program

Healthy Living with Diabetes. Diabetes Disease Management Program Healthy Living with Diabetes Diabetes Disease Management Program Healthy Living With Diabetes Diabetes Disease Management Program Background According to recent reports the incidence of diabetes (type

More information

Bupa By You. Summary

Bupa By You. Summary Bupa By You Summary Find the cover that s right for you There s a lot to take in when purchasing health insurance that s why we ve created this easy to use guide which summarises the cover that s available

More information

Early Prostate Cancer: Questions and Answers. Key Points

Early Prostate Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:

More information

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations ACO #9 Prevention Quality Indicator (PQI): Ambulatory Sensitive Conditions Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Data Source Measure Information Form (MIF)

More information

Numerator Details. - An acute or nonacute inpatient admission with a diagnosis of AOD (AOD Dependence

Numerator Details. - An acute or nonacute inpatient admission with a diagnosis of AOD (AOD Dependence Description Measure 0004: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) (National Committee for Quality Assurance) The percentage of adolescent and adult patients with

More information

Hospice and Palliative Care: Help Throughout Life s Journey. John P. Langlois MD CarePartners Hospice and Palliative Care

Hospice and Palliative Care: Help Throughout Life s Journey. John P. Langlois MD CarePartners Hospice and Palliative Care Hospice and Palliative Care: Help Throughout Life s Journey John P. Langlois MD CarePartners Hospice and Palliative Care Goals Define Palliative Care and Hospice. Describe and clarify the differences and

More information

FY2015 Hospice Wage Index Proposed Rule

FY2015 Hospice Wage Index Proposed Rule FY2015 Hospice Wage Index Proposed Rule To: NHPCO Members From: NHPCO Health Policy Team Date: May 6, 2014 Summary of FY2015 Hospice Wage Index Proposed Rule On Friday, May 2 2014, CMS released the FY2015

More information

Status Active. Reimbursement Policy Section: Anesthesia Services Policy Number: RP - Anesthesia - 001 Anesthesia Effective Date: June 1, 2015

Status Active. Reimbursement Policy Section: Anesthesia Services Policy Number: RP - Anesthesia - 001 Anesthesia Effective Date: June 1, 2015 Status Active Reimbursement Policy Section: Anesthesia Services Policy Number: RP - Anesthesia - 001 Anesthesia Effective Date: June 1, 2015 Anesthesia Policy Description: Definitions: This policy addresses

More information

Patient Electronic Alert to Key-worker System (PEAKS) Guidelines

Patient Electronic Alert to Key-worker System (PEAKS) Guidelines Patient Electronic Alert to Key-worker System (PEAKS) Guidelines This procedural document supersedes: PAT/EC 4 v.1 Guidelines for Patient Electronic Alert to Key-worker systems (PEAKS). Did you print this

More information

How Oncology Nurses Use Evidence Based Practices in Patient Navigation

How Oncology Nurses Use Evidence Based Practices in Patient Navigation How Oncology Nurses Use Evidence Based Practices in Patient Navigation Sharon Gentry, RN, MSN, AOCN, CBCN Breast Nurse Navigator Novant Health Derrick L Davis Cancer Center Winston Salem, N.C. 27103 How

More information

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) DuPage Medical Group Case Study Organization Profile Established in 1999, DuPage Medical Group (DMG) is a multispecialty

More information

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. Treatments as unique as you are Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential

More information

A Prostate and Genitourinary Multidisciplinary Oncology Clinic in a Multi-Hospital System by Richard B. Reiling, MD, FACS

A Prostate and Genitourinary Multidisciplinary Oncology Clinic in a Multi-Hospital System by Richard B. Reiling, MD, FACS A Prostate and Genitourinary Multidisciplinary Oncology Clinic in a Multi-Hospital System by Richard B. Reiling, MD, FACS In Brief At Presbyterian Cancer Center in Charlotte, N.C., we are seeing a higher

More information

We Bring The Pieces Together For You

We Bring The Pieces Together For You Modifier 25 Visit No how-de-do visits in Hematology Oncology MOASC Discussion of Meaningful Information Compliance Education We do it right. We Bring The Pieces Together For You NBC Neltner Billing & Consulting

More information

Local Coverage Article: Venipuncture Necessitating Physician s Skill for Specimen Collection Supplemental Instructions Article (A50852)

Local Coverage Article: Venipuncture Necessitating Physician s Skill for Specimen Collection Supplemental Instructions Article (A50852) Local Coverage Article: Venipuncture Necessitating Physician s Skill for Specimen Collection Supplemental Instructions Article (A50852) Contractor Information Contractor Name CGS Administrators, LLC Article

More information

ARIA ONCOLOGY INFORMATION SYSTEM RADIATION ONCOLOGY

ARIA ONCOLOGY INFORMATION SYSTEM RADIATION ONCOLOGY ARIA ONCOLOGY INFORMATION SYSTEM RADIATION ONCOLOGY The ARIA oncology information system is a powerful information and image management solution designed to support the specific clinical needs of oncology

More information

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in

More information

Circle of Life: Cancer Education and Wellness for American Indian and Alaska Native Communities. Group Discussion True False Not Sure

Circle of Life: Cancer Education and Wellness for American Indian and Alaska Native Communities. Group Discussion True False Not Sure Hospice Care Group Discussion True False Not Sure 1. There is no difference between palliative care and hospice care. Palliative care is different from hospice care. Both palliative and hospice care share

More information

Disease Management Identifications and Stratification Health Risk Assessment Level 1: Level 2: Level 3: Stratification

Disease Management Identifications and Stratification Health Risk Assessment Level 1: Level 2: Level 3: Stratification Disease Management UnitedHealthcare Disease Management (DM) programs are part of our innovative Care Management Program. Our Disease Management (DM) program is guided by the principles of the UnitedHealthcare

More information

CPT Coding Update And Other Issues

CPT Coding Update And Other Issues CPT Coding Update And Other Issues Robert E. Smith, M.D. Alison Lynch, M.D. November 13, 2013 1 Disclaimer This information is for educational and informational purposes only, and represents the understanding

More information